On the afternoon of May 30, the "Major Scientific and Technological Achievements Release Conference" of the 2023 Zhongguancun Forum was held in Beijing. The event unveiled 20 major achievements spanning four key areas: global scientific frontiers, the main economic battlefield, major national needs, and the health of the people. Among them, the Sequencing System GS100 — built on fully self‑developed core technology by Cygnus Bio — was presented to the public.
Dr. Chen Zitian, CEO of Cygnus Bio, stated: "The fluorogenic sequencing chemistry technology independently developed by Cygnus Bio has charted a new direction for the evolution of sequencing technologies. The Sequencing System GS100, which boasts completely independent intellectual property rights, reduces the sequencing error rate to as low as 0.01% (Q40). This will provide life sciences with a more precise research tool and offer a more comprehensive testing platform for healthcare. Through continuous innovation in sequencing technology, we aim to make genetic testing accessible to everyone and let technological progress better serve human health."
The 2023 Zhongguancun Forum Exhibition (China Beijing International High‑Tech Expo) was held concurrently. The exhibition featured six zones: Frontier Technology and Future Industry, Information Technology and Intelligent Manufacturing, Green and Low‑Carbon Development, Medicine and Health, Digital Economy, and Regional Innovation Cooperation. It showcased cutting‑edge achievements in fields such as blockchain, high‑end manufacturing, and gene and cell therapy. Invited to the exhibition, Cygnus Bio presented the development and translation of domestically produced high‑throughput sequencing technologies in the Medicine and Health zone. The company engaged with visitors through interactive demonstrations of the Sequencing System GS100, receiving widespread acclaim.
As a next‑generation high‑throughput sequencing company with fully independent control over its core technologies, Cygnus Bio leverages two pioneering innovations — fluorogenic sequencing chemistry and error‑correcting code (ECC) based sequencing — to launch its first product, the Sequencing System GS100. The system features a compact design, simple operation, flexible throughput, and adaptability to diverse scenarios. By continuously advancing ultra‑low‑frequency mutation detection, Cygnus Bio has achieved 99.99% sequencing accuracy (Q40), combining high precision with low background noise. The GS100 is compatible with mainstream library preparation kits and covers key genetic testing scenarios in both clinical and research settings. It has already obtained CE certification, and the company is actively advancing its registration as a Class III medical device in China.
Looking ahead, Cygnus Bio will continue to optimize its benchtop product line while introducing new Sequencing System models designed for centralized clinical testing and even simpler, more intelligent operation. These innovations aim to meet the demands of increasingly complex research and clinical applications, providing life sciences with more accurate research tools and delivering faster, simpler, and more reliable solutions for oncology, pathogen detection, reproductive health, environmental monitoring, food safety, and beyond.
